Federal Circuit vacates injunction in Amgen’s dispute with Sanofi
The permanent injunction granted by the District of Delaware in the dispute between Amgen and Sanofi/Regeneron over cholesterol-lowering treatment has been vacated, in a decision that also included some implications for the USPTO’s practice of granting broad antibody claims
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: